EUVIMEDEUVIMED entdecken
Crossref

Ricolinostat restrains osteoclastogenesis through HDAC6-associated regulation of p65 stability

Jiang Haofu, Li Wangzhi, Hao Fangdan, Wang Jialiang, Deng Qingzhou, Wu Suxin, Wang Yongkai, Chen Shuomin, Tu Junhao, Yi Mengjia, Ma Xinyi, Ping Yifan und 5 weitere

Bone · 2027

DOI: 10.1016/j.bone.2026.118102 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bone, 2027. Verfasst von Jiang Haofu und 16 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Stomatology, School and Hospital of Stomatology, Wenzhou Medical University, Wenzhou, Zhejiang, 325027, China. Hauptthemen laut MEDLINE: Histone Deacetylase 6, Osteogenesis, Osteoclasts, Hydroxamic Acids. Die Arbeit nennt 46 Literaturangaben. Gefördert von: Natural Science Foundation of Zhejiang Province, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Excessive osteoclast activity is a central driver of pathological bone loss in osteoporosis; however, the mechanisms governing osteoclast differentiation remain incompletely understood, and current therapeutic options remain limited in efficacy. Therefore, we performed high-throughput drug screening to identify candidate agents and further explored the molecular mechanisms underlying targeted osteoclastogenesis inhibition. Here, we identified ricolinostat (RICO), a selective histone deacetylase 6 (HDAC6) inhibitor, as a potent inhibitor of the receptor activator of nuclear factor-kappa B ligand (RANKL)-induced osteoclastogenesis. RICO suppresses osteoclast differentiation and reduces osteoclast-associated gene and protein expression without compromising cell viability. RICO attenuates estrogen deficiency-induced bone loss and reduces osteoclast abundance in vivo. Mechanistically, transcriptomic profiling revealed that RICO broadly suppressed osteoclastogenic, inflammatory, and metabolic programs. Specifically, by inhibiting HDAC6, RICO promoted proteasomal degradation of p65 by increasing its acetylation and ubiquitination, thereby reducing p65 protein abundance in both cytoplasmic and nuclear fractions and suppressing canonical NF-κB signaling. Collectively, these findings identify RICO-as a phase II clinical stage investigational compound with repurposing potential as a promising anti-resorptive candidate for the treatment of osteoporosis and uncover a novel mechanism whereby HDAC6 governs p65 protein stability to inhibit osteoclastogenesis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Histone Deacetylase 6OsteogenesisOsteoclastsHydroxamic AcidsPyrimidinesTranscription Factor RelAAnimalsMiceRANK LigandCell DifferentiationMice, Inbred C57BLSignal TransductionProtein StabilityRAW 264.7 CellsAcetylationBone Resorption

Stichwörter der Autor:innen

Drug repurposingNF-κB signalingOsteoclastogenesisOsteoporosisRicolinostatp65 acetylation

Substanzen

Histone Deacetylase 6ricolinostatHydroxamic AcidsPyrimidinesTranscription Factor RelARANK LigandHdac6 protein, mouse

Autor:innen und Institutionen

  • Institute of Stomatology, School and Hospital of Stomatology, Wenzhou Medical University, Wenzhou, Zhejiang, 325027, China.
  • Institute of Stomatology, School and Hospital of Stomatology, Wenzhou Medical University, Wenzhou, Zhejiang, 325027, China; Department of Oral and Maxillofacial Surgery, School of Stomatology, Wenzhou Medical University…
  • Institute of Stomatology, School and Hospital of Stomatology, Wenzhou Medical University, Wenzhou, Zhejiang, 325027, China; Department of Prosthodontics, School and Hospital of Stomatology, Wenzhou Medical University, W…
  • Institute of Stomatology, School and Hospital of Stomatology, Wenzhou Medical University, Wenzhou, Zhejiang, 325027, China. Electronic address: binli0461@gmail.com.

Förderung

  • Natural Science Foundation of Zhejiang Province
  • National Natural Science Foundation of China

Zitieren

APA

Haofu, J., Wangzhi, L., Fangdan, H., Jialiang, W., Qingzhou, D., Suxin, W., Yongkai, W., Shuomin, C., Junhao, T., Mengjia, Y., Xinyi, M., Yifan, P., Yixin, M., Yang, C., Shufan, Z., Shengbin, H., & Bin, L. (2027). Ricolinostat restrains osteoclastogenesis through HDAC6-associated regulation of p65 stability. Bone. https://doi.org/10.1016/j.bone.2026.118102

Vancouver

Haofu J, Wangzhi L, Fangdan H, Jialiang W, Qingzhou D, Suxin W, et al. Ricolinostat restrains osteoclastogenesis through HDAC6-associated regulation of p65 stability. Bone. 2027. doi:10.1016/j.bone.2026.118102

BibTeX
@article{Haofu2027,
  author = {Haofu, Jiang and Wangzhi, Li and Fangdan, Hao and Jialiang, Wang and Qingzhou, Deng and Suxin, Wu and Yongkai, Wang and Shuomin, Chen and Junhao, Tu and Mengjia, Yi and Xinyi, Ma and Yifan, Ping and Yixin, Mao and Yang, Chen and Shufan, Zhao and Shengbin, Huang and Bin, Li},
  title = {Ricolinostat restrains osteoclastogenesis through HDAC6-associated regulation of p65 stability},
  journal = {Bone},
  year = {2027},
  doi = {10.1016/j.bone.2026.118102}
}
Kostenlos starten →